tirzepatide moa weight loss Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review Weight Loss Shots | Cordova

Tirzepatide for T2D obesity SURMOUNT-2, weight -12.8/-14.7% at 10/15 mg, attenuated about 6-7 points vs non-diabetic obesity: Garvey Lancet 2023

Gastrointestinal adverse effectsparticularly nausea, vomiting, diarrhea, and constipationoccur in a dose-dependent manner

If your primary object is fat loss or immediate performance enhancement you may be better off taking it in the morning or prior to training

Nausea, reduced appetite, and burping occur commonly with subcutaneous injections too, especially during the first few weeks of treatment or after a dose increase

Neuroscience Research: Intranasal BPC-157 is studied to characterize potential nose-to-brain transport and CNS biodistribution